louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06433739: Efficacy of a Clinical Algorithm for the Selection of Peripheral Venous Catheters
Official title: Efficacy of a Clinical Algorithm for the Selection of Peripheral Venous Catheters to Reduce the Number of Catheter-Associated Complications in Hospitalized Patients: A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Catheter Related Complication
Keywords: Catheterization, Peripheral
Lead sponsor: Consorci Sanitari de l'Alt Penedès i Garraf
Sponsor class: OTHER
First posted: 2024-05-30
Enrollment: 3314
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitted to some acute care unit requiring peripheral venous catheterization

Brief summary: The aim of this observational study is to investigate the complications associated with peripheral venous catheterization based on whether a correct or incorrect catheter was used according to a clinical algorithm in patients admitted to an acute care unit. The main question it seeks to answer is:

• Are there fewer complications associated with catheterization when a correct catheter choice is made? Data from patients admitted to the acute care units of the sponsoring study center will be reviewed.


Eligibility criteria: Inclusion Criteria:

* Admitted to acute care hospital wards.
* Carriers of a peripheral venous catheter.
* With the study evaluation criteria documented in their medical records.

Exclusion Criteria:

* Admitted to gynecology, obstetrics, and pediatrics wards.
* Admitted to the emergency department and intensive care units

Primary outcomes:
measure: Catheters removed due to complications associated with the use of a peripheral venous catheter
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: Selection of the peripheral venous catheter
timeFrame: Through study completion, an average of 1 year
measure: Complications associated with the use of a peripheral venous catheter
timeFrame: Through study completion, an average of 1 year
Other outcomes:
Locations:
city: Sant Pere De Ribes
country: Spain
facility: Consorci Sanitari Alt Penedes i Garraf
state: Barcelona
Study officials:
affiliation: CSAPG
name: Esther Moreno
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06888739: Development and Validation of Interpretable Machine Learning Models Incorporating Paraspinal Muscle Quality for to Predict Cage Subsidence Risk Followingposterior Lumbar Interbody Fusion
Official title: Development and Validation of Interpretable Machine Learning Models Incorporating Paraspinal Muscle Quality for to Predict Cage Subsidence Risk Followingposterior Lumbar Interbody Fusion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Degenerative Lumbar Diseases
Cage
Machine Learning
Keywords: Degenerative lumbar disease
Cage subsidence
Machine learning
Lead sponsor: First Affiliated Hospital of Suzhou Medical College
Sponsor class: OTHER
First posted: 2025-03-21
Enrollment: 720
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This retrospective study included patients with degenerative lumbar diseases who underwent single-level PLIF at the First and Second Affiliated Hospitals of Soochow University (January 2018-October 2023).A total of 620 patients from the First Affiliated Hospital comprised the training set, while 100 patients from the Second Affiliated Hospital formed the external validation set. The study adhered to the Declaration of Helsinki and was approved by the institutional ethics committee.

Brief summary: The study focuses on identifying risk factors for cage subsidence after posterior lumbar interbody fusion (PLIF) and developing an interpretable machine learning model to predict these risks. It analyzes patients from two large teaching hospitals, using clinical, radiographic, and surgical parameters, including paraspinal muscle indices and bone density markers. A web-based application was developed to facilitate real-time clinical risk assessments using the machine learning model, enhancing surgical planning and reducing subsidence risks.


Eligibility criteria: Inclusion Criteria:

1. confirmed lumbar disc herniation, spinal stenosis, or spondylolisthesis based on clinical and imaging findings;
2. patients who failed conservative treatment for ≥3 months or experienced recurrence and underwent surgery for the first time;
3. minimum 12-month follow-up.

Exclusion Criteria:

1. prior spinal surgery;
2. spinal deformity or severe instability;
3. lumbar tuberculosis, infection, tumor, or severe bone destruction;
4. incomplete or lost follow-up.

Primary outcomes:
measure: Bone density imaging indicator: Vertebral Bone Quality (VBQ)
timeFrame: Preoperative measurement for PLIF (Posterior Lumbar Interbody Fusion)
Secondary outcomes:
Other outcomes:
Locations:
city: Jiangsu
country: China
facility: The First Affiliated Hospital of Soochow University Medical Record and Imaging System
state: SuZhou
Study officials:
References:
Clinical trial NCT00542139: Evaluation of Diprospan Injection to the Knee on Rehabilitation of Patients After TKR of the Contralateral Knee
Official title: Evaluation of the Efficacy of Diprospan Injection to the Knee on Rehabilitation of Patients With Bilateral Knee Osteoarthritis After TKR of the Contralateral Knee.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Osteoarthritis
Keywords: Osteoarthritis
Knee arthroplasty
Steroid injection
Rehabilitation
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2007-10-10
Enrollment: 50
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is performed to assess the influence of intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate) into osteoarthritic knee in patients who undergo a total knee replacement of their contralateral knee.

The study population will include 50 patients with bilateral knee osteoarthritis, admitted for their first knee replacement surgery. Only patients with older than 50 years with primary osteoarthritis will be included. The patients will be randomized into 2 groups. Intervention group will receive an injection of 2ml Diprospan diluted in 10 ml Bupivocaine. The control group will receive an injection of 10ml of Bupivocaine. All patients will be followed after 6 weeks and three functional rehabilitation and pain scores will be assessed (VAS pain score, Timed Up and Go Score and Functional Ambulatory Category Scale).


Eligibility criteria: Inclusion Criteria:

* Age older than 50
* Bilateral primary knee osteoarthritis
* Undergoing knee arthroplasty

Exclusion Criteria:

* Active infection
* Allergy to medication compounds
* Pregnancy

Primary outcomes:
measure: Visual analogue pain score
timeFrame: 6 weeks
Secondary outcomes:
measure: Timed Up and Go Score
timeFrame: 6 weeks
measure: Functional Ambulatory Category Scale
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
affiliation: Hadassah Medical Organization
name: Leonid Kandel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06917339: Retrospective Analyses of TrakStar Database
Official title: Retrospective Analyses Evaluating the Real-World Effectiveness of NeuroStar® TMS and the Factors Associated With Clinical Outcomes
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Depression
Obsessive-Compulsive Disorder
Anxiety Depression
Keywords: TMS
Lead sponsor: Neuronetics
Sponsor class: OTHER
First posted: 2025-04-08
Enrollment: 156000
Sex: ALL
Minimum age (years): 5
Maximum age (years): 120
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients treated with NeuroStar Advanced TMS Therapy on or after November 1, 2008, and whose treatment information was entered in the Neuronetics TrakStar database.

Brief summary: In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.


Eligibility criteria: Inclusion Criteria:

* Male or female reported in database and not an invalid entry
* Age reported and not an invalid entry
* Treatment date of November 01, 2008 or later.

Exclusion Criteria:

• Incomplete information on treatment parameters

Primary outcomes:
measure: Change in clinical assessment score from baseline to post-treatment
timeFrame: 8 weeks
Secondary outcomes:
measure: Age at baseline and its correlation to change in score post treatment
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Malvern
country: United States
facility: Neuronetics
state: Pennsylvania
Study officials:
affiliation: Neuronetics
name: Eleanor Cole, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00694239: Risk Assessment and Treat Compliance in Hypertension Education Trial
Official title: Evaluation of the Effect of Cardiovascular Risk Assessment in Treatment Compliance in Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Dyslipidemia
Keywords: hypertension
compliance
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
Collaborators: name: University of Western Ontario, Canada
name: The Physicians' Services Incorporated Foundation
First posted: 2008-06-10
Enrollment: 100
Sex: ALL
Minimum age (years): 30
Maximum age (years): 84
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The RATCHET study assesses if patient knowledge of estimated cardiovascular risk at current and recommended target blood pressure levels improves compliance in the management of hypertension.


Eligibility criteria: Inclusion Criteria:

* Essential hypertension (new diagnosis or established diagnosis) meeting criteria for pharmacologic therapy as defined by current guidelines

Exclusion Criteria:

* Lack of written informed consent
* Previous myocardial infarction
* Previous stroke
* Congestive heart failure
* Stage 3 or greater chronic kidney disease
* Pregnancy
* Usage of medication bubble/blister package

Primary outcomes:
measure: Medication Compliance
timeFrame: 1 year
Secondary outcomes:
measure: Patient perception of cardiovascular risk
timeFrame: 1 year
measure: Pilot Feasibility Study
timeFrame: 1 year
measure: Blood Pressure
timeFrame: 1 year
measure: Cholesterol Level
timeFrame: 1 year
measure: Framingham Risk Score (stroke and coronary artery disease)
timeFrame: 1 year
Other outcomes:
Locations:
city: London
country: Canada
facility: University of Western Ontario
state: Ontario
Study officials:
affiliation: Western University, Canada
name: Bryan J Har, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Western University, Canada
name: George K Dresser, PhD, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01532739: Making Memory Better for Seniors With Mild Cognitive Impairment
Official title: Neuropsychological Intervention for a Seniors Mental Health Population With Mild Cognitive Impairment
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Mild Cognitive Impairment
Keywords: Mild Cognitive Impairment
Aging
Memory
Executive Function
Cognitive Intervention
Memory Training
Mental Health
Lead sponsor: Nova Scotia Health Authority
Sponsor class: OTHER
Collaborators: name: Nova Scotia Health Research Foundation
First posted: 2012-02-14
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the feasibility and effectiveness of a cognitive training group in individuals with Mild Cognitive Impairment, using a new paradigm that will optimize ecological validity by (1) focusing on everyday memory problems, (2) supplementing traditional memory training with the teaching of an empirically-supported problem-solving approach, and (3) employing a clinically representative sample of individuals with MCI (e.g., not excluding those with mild affective symptoms).


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Mild Cognitive Impairment

Exclusion Criteria:

* Clinical diagnosis of dementia
* History of neurological conditions known to impair cognition
* History of alcohol or drug abuse
* History of chronic psychiatric illness
* Current symptoms of moderate to severe depression (Geriatric Depression Scale \>19) or anxiety (Beck Anxiety Inventory \>15)

Primary outcomes:
measure: Change in everyday memory functioning
timeFrame: Measured at baseline and months 3, 5, 8
Secondary outcomes:
measure: Change on traditional memory testing
timeFrame: Measured at baseline and months 3, 5, 8
measure: Change in memory perception
timeFrame: Measured at baseline and months 3, 5, 8
measure: Change in mood (i.e., self-report symptoms of depression)
timeFrame: Measured at baseline and months 3, 5, 8
measure: Change in mood (i.e., self-report symptoms of anxiety)
timeFrame: Measured at baseline and months 3, 5, 8
measure: Change in other psychiatric symptoms (informant-report)
timeFrame: Measured at baseline and months 3, 5, 8
measure: Change in quality of life
timeFrame: Measured at baseline and months 3, 5, 8
measure: Change in caregiver burden
timeFrame: Measured at baseline and months 3, 5, 8
measure: Feasibility
timeFrame: Measured at end of study
Other outcomes:
Locations:
city: Dartmouth
country: Canada
facility: Neuropsychology Service, Nova Scotia Hospital
state: Nova Scotia
Study officials:
affiliation: Nova Scotia Health Authority
name: Karen A Chipman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05855239: Quantification of Hepatic Steatosis With Different Ultrasound Frequency
Official title: Quantification of Hepatic Steatosis in Patients With Fatty Liver Disease Using Attenuation Imaging With Different Ultrasound Frequency
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Fatty Liver
Fatty Liver, Nonalcoholic
Ultrasound
Keywords: Hepatic steatosis
Quantification
Ultrasound
Attenuation coefficient
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
Collaborators: name: Canon Medical Systems, Korea
First posted: 2023-05-11
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants at risk of fatty liver disease

Brief summary: The objective of this study is: (1) to compare the feasibility (technical successes rate and reliability) in measuring attenuation coefficient between two different frequencies (3MHz, 4MHz) of ultrasound beam; (2) to evaluate and compare the diagnostic performance of attenuation coefficient for steatosis using two different frequencies (3MHz, 4MHz) of ultrasound beam by comparison with the pathologic results acquired by liver biopsy or surgery.

Detailed description: Investigators measure the distance between the skin and liver capsule on B-mod images.

Investigators place a region of interest (ROI) avoiding reverberation artifacts and acquire attenuation coefficient for five times.

For participants who require a liver biopsy, investigators try to target the same area in the liver, where ROI was placed.

Investigators evaluate hepatic steatosis, lobular inflammation, and fibrosis of tissue of the liver using a scoring system suggested by Nonalcoholic Steatohepatitis Clinical Research Network.

Eligibility criteria: Inclusion Criteria:

* Participants who are candidates for liver donation and scheduled liver biopsies for assessment of hepatic steatosis
* Participants suspected of nonalcoholic fatty liver disease and scheduled for liver biopsy or surgery

Exclusion Criteria:

* Participants with a BMI of less than 23
* Participants underwent liver transplantation or right hepatectomy
* Participants who have a large mass in the right liver
* Participants who have a bleeding tendency (platelet count \< 80000, prothrombin time and international normalized ratio \> 1.5)

Primary outcomes:
measure: Attenuation coefficient (3MHz vs. 4MHz) in attenuating imaging
timeFrame: During procedure
measure: Percentage of fat within hepatocyte in pathological specimen
timeFrame: During procedure
Secondary outcomes:
Other outcomes:
Locations:
city: P'ungnap-tong
country: Korea, Republic of
facility: Asan medical center
state: Seoul
Study officials:
affiliation: Asan Medical Center
name: JongKeon Jang, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02189239: Efficacy Study of Zeller Entspannung Film Coated Tablets on Acute Stress
Official title: A Phase IV, Randomised, Placebo Controlled Study to Investigate the Effects of Zeller Entspannung Film Coated Tablets on Cortisol Responses in Healthy Volunteers With Acute Stress
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: The Primary Condition Studied for This Trial is Acute Stress
Lead sponsor: Max Zeller Soehne AG
Sponsor class: INDUSTRY
First posted: 2014-07-14
Enrollment: 72
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the STRESS trial is to investigate in a mode of action setting the effect of Zeller Entspannung film coated tablets on saliva cortisol response versus Placebo after acute stress in healthy male volunteers. In addition, data on safety and tolerability of Zeller Entspannung will be obtained.

A third arm including no treatment is tested as well. Approximately 72 healthy volunteers will be included into this randomized, double blind study. Study duration will be 7 days, study medication intake will be over 4 days: participants will take the medication one tablet three times a day (morning, midday, evening) the first 3 days, whereas on day 4 only two tablets will be taken (morning and midday).


Eligibility criteria: Inclusion Criteria:

* Age:18 - 45 years
* Written informed consent
* Male gender

Exclusion Criteria:

* Any acute or chronic somatic or psychiatric disorder
* Smoking
* Any clinically relevant hepatic disorder
* Any clinically relevant renal disorder
* Any clinically relevant cardiac disorder
* Any clinically relevant respiratory disease (e.g. Asthma)
* Diabetes mellitus
* Any abnormal lab values suggesting diseases from exclusion criteria
* Known allergies to trial medication and excipients
* Alcohol or other drug abuse (e.g. cannabis)
* Concomitant participation in another clinical trial or \<4 weeks ago
* Participation in any psychotherapy
* Already participated in a TSST

Primary outcomes:
measure: The primary objective is to demonstrate in healthy male volunteers that Zeller Entspannung reduces overall saliva cortisol level (AUCg) after acute stress compared with a placebo.
timeFrame: 4 days
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Phase I Research Unit, University Hospital Basel
Study officials:
References:
Clinical trial NCT06873139: FIT4Life Text Message Program
Official title: FIT4Life Text Message Program
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Physical Activity
Behavior Change
Lead sponsor: Children's Mercy Hospital Kansas City
Sponsor class: OTHER
First posted: 2025-03-12
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: FIT4Life is a text message based physical activity project that includes one baseline week and 26 weeks of intervention delivery. Study participants will be provided with fitness trackers to support their physical activity goals. The text messages are intended to motivate participants to engage in physical activity throughout the week, but do not prescribe specific exercises/workout regimens for participants to follow.


Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Able to read, write, and speak English
* Currently a Diabetes Prevention Program group or in a similar group that is recruited by the external community partner (Our Healthy Jackson County)

Exclusion Criteria:

* Does not meet the inclusion criteria listed above

Primary outcomes:
measure: Acceptability and preferences
timeFrame: From enrollment to the end of program at 27 weeks
Secondary outcomes:
measure: Change in Physical Activity Minutes
timeFrame: From enrollment to the end of program at 27 weeks
measure: Change in Physical Steps
timeFrame: From enrollment to the end of program at 27 weeks
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: Kansas City Community
state: Missouri
Study officials:
References: